AKCA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AKCA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Akcea Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2020 was $479.0 Mil. Akcea Therapeutics's Total Assets for the quarter that ended in Jun. 2020 was $527.9 Mil. Therefore, Akcea Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2020 was 0.91.
The historical rank and industry rank for Akcea Therapeutics's Equity-to-Asset or its related term are showing as below:
During the past 6 years, the highest Equity to Asset Ratio of Akcea Therapeutics was 0.91. The lowest was -0.67. And the median was 0.75.
The historical data trend for Akcea Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akcea Therapeutics Annual Data | |||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.84 | -1.66 | 0.62 | 0.76 | 0.91 |
Akcea Therapeutics Quarterly Data | ||||||||||||||||||||
Dec14 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.85 | 0.85 | 0.91 | 0.91 | 0.91 |
For the Biotechnology subindustry, Akcea Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Akcea Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Akcea Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Akcea Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as
Equity to Asset (A: Dec. 2019 ) | = | Total Stockholders Equity | / | Total Assets |
= | 543.004 | / | 599.25 | |
= | 0.91 |
Akcea Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2020 is calculated as
Equity to Asset (Q: Jun. 2020 ) | = | Total Stockholders Equity | / | Total Assets |
= | 479.028 | / | 527.937 | |
= | 0.91 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akcea Therapeutics (NAS:AKCA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Akcea Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael J. Yang | director | C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
Joseph Iii Klein | director | C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511 |
Sandford D Smith | director | C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
B Lynne Parshall | director | 2855 GAZELLE COURT, CARLSBAD CA 92010 |
Joshua F. Patterson | officer: General Counsel | C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210 |
Damien Mcdevitt | director, officer: Chief Executive Officer | C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010 |
Alex G. Howarth | officer: Chief Operating Officer | C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210 |
Kyle Jenne | officer: Chief Commercial Officer | C/O AKCEA THERAPEUTICS, INC. 22 BOSTON WHARF ROAD, 9TH FLOOR BOSTON MA 02210 |
William T. Andrews | officer: Chief Medical Officer | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
Barbara Yanni | director | 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406 |
Michael Dennis Price | officer: Chief Financial Officer | |
Elaine Hochberg | director | C/O AKCEA THERAPAEUTICS 55 CAMBRIDGE PKWY, STE 100 CAMBRIDGE MA 02142 |
Isis Pharmaceuticals Inc | 10 percent owner | 2855 GAZELLE COURT, CARLSBAD CA 92010 |
Michael F Maclean | officer: Chief Financial Officer | 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
Paula Soteropoulos | director, officer: Chief Executive Officer | 49 WINONA STREET, PEABODY MA 01960 |
From GuruFocus
By PRNewswire PRNewswire • 06-09-2020
By PRNewswire PRNewswire • 06-08-2020
By PRNewswire PRNewswire • 10-30-2020
By PRNewswire PRNewswire • 08-24-2020
By ACCESSWIRE ACCESSWIRE • 09-03-2020
By PRNewswire PRNewswire • 09-22-2020
By Business Wire Business Wire • 09-05-2020
By PRNewswire PRNewswire • 08-29-2020
By PRNewswire PRNewswire • 08-13-2020
By PRNewswire PRNewswire • 09-01-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.